BofA raised Syndax (SNDX) PT to $28, cites heavy pre-announcements lowering earnings impact
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising low-cost stocks to buy now. On February 3, Bank of America analyst Jason Zemansky raised the firm’s price target on Syndax to $28 from $27 and kept a Buy rating. Zemansky noted that...
Insider Monkey